Raloxifene Hydrochloride Patent Expiration
Raloxifene Hydrochloride is Used for preventing and treating osteoporosis in postmenopausal women and inhibiting bone resorption, as well as for preventing breast cancer. It was first introduced by Eli Lilly And Co
Raloxifene Hydrochloride Patents
Given below is the list of patents protecting Raloxifene Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Evista | US6458811 | Benzothiophenes formulations containing same and methods |
Mar 10, 2017
(Expired) | Lilly |
| Evista | US6797719 | Benzothiophenes, formulations containing same, and methods |
Mar 10, 2017
(Expired) | Lilly |
| Evista | US6894064 | Benzothiophenes, formulations containing same, and methods |
Mar 10, 2017
(Expired) | Lilly |
| Evista | US8030330 | Benzothiophenes, formulations containing same, and methods |
Mar 10, 2017
(Expired) | Lilly |
| Evista | US5478847 | Methods of use for inhibiting bone loss and lowering serum cholesterol |
Mar 02, 2014
(Expired) | Lilly |
| Evista | US5811120 | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
Mar 02, 2014
(Expired) | Lilly |
| Evista | US5972383 | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
Mar 02, 2014
(Expired) | Lilly |
| Evista | USRE39050 | Methods of use for inhibiting bone loss and lowering serum cholesterol |
Mar 02, 2014
(Expired) | Lilly |
| Evista | US5393763 | Methods for inhibiting bone loss |
Jul 28, 2012
(Expired) | Lilly |
| Evista | US5457117 | Method for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B][2-(piperidin-1-yl)ethoxyphenylimethanone hydrochloride |
Jul 28, 2012
(Expired) | Lilly |
| Evista | US6906086 | Methods for inhibiting bone loss |
Jul 28, 2012
(Expired) | Lilly |
| Evista | USRE38968 | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride |
Jul 28, 2012
(Expired) | Lilly |
| Evista | USRE39049 | Methods for inhibiting bone loss |
Jul 28, 2012
(Expired) | Lilly |
Raloxifene Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Raloxifene Hydrochloride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE2, PHASE3 |